Cipla to pump $89M into building South African biosimilars plant

Cipla
Subhanu Saxena, CEO of Cipla Pharma of India.
Saxena headshot
Subhanu Saxena

India’s Cipla said it will invest $89 million (1.3 billion rand) to build a new production facility in South Africa that will focus on the manufacturing of biosimilars.

The plant, which is being touted at the first bio-cluster facility on the African continent, will produce biosimilar drugs made from living organisms that would be used in the treatment of cancer and other diseases. Construction is expected to start early next year, with full operations likely to begin by 3Q 2018, The Financial Express reported.

The company’s CEO, Subhanu Saxena, told the newspaper that the manufacturing base in South Africa will give the company opportunities for supply chain partners and related companies to become involved in the market.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

The site for the plant wasn’t cited in the Express story.

Earlier this year, Cipla entered the U.S. market when it acquired a 350,000-square-foot manufacturing plant in Long Island as part of its $550 million buyout of InvaGen Pharmaceuticals, a Hauppauge, NY-based generics maker with 32 products on the market and 30 in the pipeline. Cipla also acquired Exelan Pharmaceuticals, a Lawrenceville, GA, operation that markets and sells InvaGen products into the government and institutional markets.

- check out the Express story

Related Articles: 
Cipla secures first U.S. manufacturing plant

Read more on

Suggested Articles

Neopharma, which has been buying and building plants for several years, is buying a sterile injectables plant and assets in Japan from India’s Lupin. 

Already knocked by the FDA four times this year, Dr. Reddy’s now has a fifth Form 483 to dwell on. This time it’s at a plant with a history of faults.

In a warning letter, the FDA details how a Chinese OTC drugmaker handed over documents faked just for the agency's inspection—and admitted it.